Sponsored by:
Breaking Boundaries in Targeted Protein Degradation
Targeted protein degradation is redefining what’s possible in modern drug discovery. By harnessing the cell’s own machinery to eliminate disease-causing proteins, degraders and molecular glues are moving science beyond traditional inhibition—and into a new era of precision and control.
This webinar brings together experts from two leading research centers—one pioneering next-generation molecular glue discovery, and the other advancing VHL-based degrader platforms for oncology. Together, they’ll explore the science, strategy, and design principles that are breaking the old rules of drug development and opening up vast new therapeutic space.
Who Should Attend:
- Scientists and leaders in medicinal chemistry, chemical biology, and drug discovery.
- Researchers exploring emerging therapeutic modalities and the future of small molecules.
- Drug Discovery professionals who are interested in knowing how degraders and molecular glues are reshaping traditional drug development workflows.
Why You Should Join:
- Hear from top-tier research institutions at the forefront of protein degradation science.
- Gain practical insights into how molecular glues and PROTACs are expanding druggable targets.
- Understand how evolving assay cascades and screening methods are helping advance compounds beyond the traditional Rule of 5 (Ro5) limitations.
What You’ll Learn:
- The key mechanistic and design differences between degraders and molecular glues.
- How leading teams are engineering selectivity and efficacy across complex protein systems.
- The changing landscape of assay cascades and experimental strategies needed to progress non-traditional, beyond Ro5 compounds.
- Where the field is headed next—and how to position your organization at the cutting edge.
